884004-48-2Relevant articles and documents
Fused ring compounds as FGFR4 inhibitors
-
, (2021/10/27)
The heart toxicity is low. High selectivity as FGFR4 inhibitor fused ring compounds, pharmaceutical compositions containing said compounds, useful intermediates and for preparing said compounds, and methods of treating cell proliferative diseases such as cancer using the compounds of the present invention.
CYTOMEGALOVIRUS INHIBITOR COMPOUNDS
-
, (2013/10/22)
Compounds of Formula (I) wherein n, A, R1, R2, R3 and R5 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists
Blum, Charles A.,Caldwell, Timothy,Zheng, Xiaozhang,Bakthavatchalam, Rajagopal,Capitosti, Scott,Brielmann, Harry,De Lombaert, Stéphane,Kershaw, Mark T.,Matson, David,Krause, James E.,Cortright, Daniel,Crandall, Marci,Martin, William J.,Murphy, Beth Ann,Boyce, Susan,Jones, A. Brian,Mason, Glenn,Rycroft, Wayne,Perrett, Helen,Conley, Rachael,Burnaby-Davies, Nicola,Chenard, Bertrand L.,Hodgetts, Kevin J.
experimental part, p. 3330 - 3348 (2010/09/07)
The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antago